BIO-TECHNE CORPORATION ($NASDAQ:TECH) announced their fiscal year 2023 fourth quarter earnings on August 8, 2023, with total revenue amounting to USD 301.3 million, a 4.5% growth from the same three-month period in the previous year. Additionally, net income for the quarter increased by 22.7% year over year to USD 75.5 million.
The company’s stock opened at $83.4 and closed at $84.3, representing a 3.7% increase from its previous closing price of 81.3. This is an impressive performance for the company, indicating stability and growth in the market. Its innovative products and services are used in applications such as tissue engineering, drug discovery, and personalized medicine. The company’s advanced technologies provide unique solutions for researchers and medical professionals to better address complex biological challenges. These positive results show that the company is continuing to experience strong growth and that it is on track to achieve its financial goals for this fiscal year.
Overall, BIO-TECHNE CORPORATION’s fourth quarter earnings report indicates a healthy and growing business. With its innovative products and services, the company is well positioned to maintain its position as a leader in the life sciences industry. Investors should keep an eye on the company as it continues to grow and develop its products and services. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Bio-techne Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bio-techne Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bio-techne Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Bio-techne Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Bio-techne Corporation Intrinsic Value Calculation
At GoodWhale, we analyze the fundamentals of BIO-TECHNE CORPORATION stock and have determined that the company is a strong investment. Our proprietary Valuation Line indicates that the intrinsic value of a single share of BIO-TECHNE CORPORATION is around $102.2. Currently, BIO-TECHNE CORPORATION’s stock is trading at $84.3, which is a fair price and represents 17.5% undervalued shares. This makes BIO-TECHNE CORPORATION an attractive investment for those looking for good returns. More…
Risk Rating Analysis
Star Chart Analysis
In the realm of biotechnology, there is fierce competition between companies to provide the best products and services. Among these companies is Bio-Techne Corp, which competes against Proteomics International Laboratories Ltd, AEterna Zentaris Inc, AXIM Biotechnologies Inc, and others. While each company has its own strengths and weaknesses, Bio-Techne Corp has been able to distinguish itself through its innovative products and cutting-edge technology. As the biotechnology landscape continues to evolve, it will be interesting to see how these companies adapt and change in order to stay ahead of the competition.
– Proteomics International Laboratories Ltd ($ASX:PIQ)
Proteomics International Laboratories Ltd is a company that specializes in providing proteomics services. Its market cap as of 2022 was 110.87M, and its ROE was -75.41%. The company’s main services include proteomics research, biomarker discovery, and protein quantification. Proteomics International Laboratories Ltd has a strong focus on quality and customer service, and has a team of experienced scientists that are dedicated to helping their clients achieve success.
– AEterna Zentaris Inc ($TSX:AEZS)
Aeterna Zentaris is a Canadian biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic drugs for the treatment of cancer and endocrine disorders. As of 2022, the company had a market capitalization of $25.01 million and a return on equity of -14.54%. The company’s products include the cancer drug Macrilen, which is approved for the treatment of acromegaly, and the endocrine disorder drug Zoptarelin Doxorubicin, which is in clinical development for the treatment of breast cancer.
– AXIM Biotechnologies Inc ($OTCPK:AXIM)
AXIM Biotechnologies Inc is a clinical stage pharmaceutical company focused on the development of cannabinoid-based therapeutics. The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions.
The company’s market cap is 10.55M as of 2022. The company’s ROE is 223.83%.
The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions. The company is focused on the development of cannabinoid-based therapeutics to treat pain, inflammation, anxiety, and other conditions.
Bio-Techne Corporation recently released its financial results for the fourth quarter of fiscal year 2023, ending June 30th, 2023. Revenue grew by 4.5% year-over-year to $301.3 million, while net income increased by 22.7% to $75.5 million. On the same day of the announcement, the stock price moved up, suggesting that investors are encouraged by the company’s performance. Going forward, investors may want to keep an eye on Bio-Techne Corporation to gauge how the company performs in the next quarter and whether the positive trend continues.